Amr Mohamed, MD
- Director, Neuroendocrine Tumors Program, UH Seidman Cancer Center
- Associate Professor, CWRU School of Medicine
- Specialty: Medical Oncology, Hematology and Oncology
-
Location:UH Seidman Cancer Center
11100 Euclid Ave
Cleveland, OH 44106
- Call: 440-656-2315
Biography: Amr Mohamed, MD
Expertise
Certifications & Memberships
- Medical Oncology - American Board of Internal Medicine
- Internal Medicine - American Board of Internal Medicine
Education
Fellowship | Medical Oncology
Medical Oncology - BARBARA ANN KARMANOS CANCER INSTITUTE (2016 - 2018)
Residency | Internal Medicine
Internal Medicine - Grady Memorial Hospital (2013 - 2016)
Research Fellowship | Medicine
Medicine - Emory University School Of Medicine (2010 - 2013)
Research Fellowship | Cardiology
Cardiology - Emory University School Of Medicine (2010 - 2013)
Medical Education
Cairo University Faculty Of Medicine (2007)
About
Amr Mohamed, MD, is a board-certified medical oncologist and internal medicine specialist at UH Seidman Cancer Center and an associate professor of gastrointestinal medical oncology and neuroendocrine tumors at Case Western Reserve University School of Medicine. His special clinical interests include the management of gastrointestinal and neuroendocrine malignancies.
Since joining University Hospitals, Dr. Mohamed has created a comprehensive neuroendocrine tumors program at UH Seidman Cancer Center, which now has more than ten neuroendocrine tumor (NET) experts from different subspecialties. He currently serves as director of the program.
Dr. Mohamed received his medical doctorate from the Cairo University School of Medicine in 2007 followed by three years of internal medicine training at Ministry of Health affiliated hospitals. He then came to the United States to complete a research fellowship at Emory University School of Medicine, after which he finished his internal medicine training at Morehouse School of Medicine in Atlanta, Georgia. He went on to complete a fellowship in medical oncology at the Karmanos Cancer Institute at Wayne State University in Detroit, Michigan, followed by an instructorship year in neuroendocrine tumors and GI malignancies at the Moffitt Cancer Center in Tampa, Florida.
An active member of numerous medical societies, Dr. Mohamed also serves on the educational committee of the North American Neuroendocrine Tumors Society (NANETs). He has authored many peer-reviewed papers and received two merit awards from the American Society of Clinical Oncology (ASCO).
Featured Videos
Watch to find out more about this University Hospitals provider.
Industry Relationships
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Amr Mohamed did not disclose any Outside Relationships with Industry.